GMGabriela Mercado

Gabriela Mercado

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gabriela Mercado has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neuroinflammation is an early pathological process in a mouse model of prodromal Parkinson’s disease

    by Gabriela Mercado, Lucas Stetzik, Emily Schulz, Lindsay Meyerdirk, Allison Lindquist, Lorna Cohen, Martha L. Escobar Galvis, Jennifer A. Steiner, Darren Moore, Daniel W. Wesson, et al.

    Approximately 90% of Parkinson’s disease (PD) patients exhibit olfactory deficits, which often precedes motor symptoms by years, and are a robust predictor for PD and subsequent cognitive decline. Pathological changes in the PD olfactory system, particularly α-synuclein (αSyn) pathology in the olfactory bulb (OB) and severe involvement of the anterior olfactory nucleus (AON), are distinct from normal aging. However, the causal link between αSyn aggregation and functional impairment, potentially involving cytotoxicity and neuroinflammation, remains elusive. To investigate these early pathological events, we utilized a prodromal PD model that we have previously characterized, involving the unilateral OB injection of αSyn pre-formed fibrils (PFF) in wild-type mice. This triggers the transneuronal spread of pathogenic αSyn, and olfactory dysfunction starting at 1-month post-injections. Here we report on neuropathological and inflammatory events 1–3 month following injection of PFFs into the OB. Following PFF injection, αSyn pSer129 pathology progressively accumulated bilaterally in the AON and ipsilateral in the piriform cortex (PCX) over three months. Stereological quantification revealed no significant neuronal loss in the AON or PCX during this 1–3 month interval, indicating that olfactory impairment precedes overt neurodegeneration. Instead, we identified the upregulation of pro-inflammatory genes ( Il- 1β and Il-6 ), significant microglial reactivity, and sustained astrogliosis within olfactory structures. These findings identify neuroinflammation as a key early mediator linking αSyn pathology to olfactory dysfunction in the absence of neuronal loss. This suggests a critical window for therapeutic intervention and highlights neuroinflammatory markers as potential biomarkers for the prodromal phase of PD. Highlights: Neuroinflammation Precedes Neuron Loss. Inflammation is an early pathological process that is detected before any significant loss of NeuN-positive neurons in olfactory structures. Progressive αSyn pSer129 spreading. Pathological αSyn pSer129 progressively spreads transneuronally from the injection site in the OB to secondary olfactory structures (AON and PCX) within 1 to 3 months. Early Microglial Reactivity. The spreading of αSyn pSer129 pathology rapidly induces microglial reactivity, which is prominent at the 1- and 2-month time points. Persistent Astrogliosis. Astrogliosis is also an early and persistent component of the neuroinflammatory response, starting at 1 month and remaining detectable through 3 months, suggesting a sustained inflammatory environment.

  • Open Access

    Chronic urinary tract infections cause persistent microglial changes in a humanized ɑ-synuclein mouse model

    by Gabriela Mercado, Ann-Céline Clabout, Vanessa Howland, Ehsan Arkin, Anna Barber Janer, Dieter Plessers, Jennifer A Steiner, Wanli W Smith, Tom Hannan, Patrik Brundin, et al.

    Background: Urinary tract infections (UTIs) have recently been linked to the onset of multiple synucleinopathies including Parkinson's disease (PD) and multiple system atrophy (MSA). UTIs are more common in people with PD or MSA, than in the general population and within these patient groups the incidence of UTIs is evenly distributed between men and women. UTIs are especially common during disease, but also in the years before clinical diagnosis. Objective: The mechanisms by which UTIs may contribute to the development and progression of PD or MSA are not well understood. In this work, we evaluate the neuroinflammatory effects of recurrent UTIs on the brain. Methods: In a humanized mouse model of ɑ-synuclein, we find that repeated administration of uropathogenic E. coli result in sustained UTIs, or a non-resolving chronic UTI phenotype with persistent bacteriuria. Using this model, we investigate the effects of repeated chronic UTIs on neuroinflammation and synucleinopathy in the brain. Results: Recurrent UTIs lead to behavioral motor changes and are accompanied by persistent neuroinflammatory changes in multiple brain areas. Affected regions with microglial changes involve multiple lower brainstem areas responsible for sickness behavior, including the dorsal vagal complex, and the cingulate cortex. Conclusions: These results suggests that recurrent UTIs can have lasting impact on the brain, and it warrants further investigation of the potential role of UTIs in the disease progression of synucleinopathies and related neurological disorders.